EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Antibody–drug conjugates transform the outcome of individuals with low‐HER2‐expression advanced breast cancer

Fei Qu, Rongrong Lu, Qian Liu, Xuefang Wu, Xiang Huang, Yongmei Yin iD, Wei Li

Cancer · 15.04.2024 · 130 (S8) · 1392-1402

DOI: 10.1002/cncr.35205 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer, online erschienen am 25.01.2024. Verfasst von Fei Qu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Immunoconjugates, Antineoplastic Agents. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 62 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Chinese Society of Clinical Oncology Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibody–drug conjugates (ADCs)—a groundbreaking class of agents for targeted oncological therapies—consist of monoclonal antibodies with strong antigenic specificity coupled with highly active cytotoxic agents (also referred to as “payloads”). Over the past 2 decades, breast cancer research has evolved into a focal point for the research and development of ADCs, leading to several recent landmark publications. These advancements are ushering in a transformative era in breast cancer treatment and redefining conventional classifications by introducing a prospective subtype termed “HER2‐low.” The latest iterations of ADCs have demonstrated enhanced efficacy in disease management through the optimization of various factors, notably the incorporation of the bystander effect. These conjugates are no longer limited to the oncogenic driver human epidermal growth factor receptor 2 (HER2). Other antigens, including human epidermal growth factor receptor 3 (HER3), trophoblast cell surface antigen 2 (Trop‐2), zinc transporter ZIP6 (LIV‐1), and folate receptor α (FRα), have recently emerged as intriguing tumor cell surface nondriver gene targets for ADCs, each with one or more specific ADCs that showed encouraging results in the breast cancer field. This article reviews recent advances in the application of ADCs in the treatment of HER2‐low breast cancer. Additionally, this review explores the underlying factors contributing to the impact of target selection on ADC efficacy to provide new insights for optimizing the clinical application of ADCs in individuals with low HER2 expression in advanced breast cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsImmunoconjugatesAntineoplastic AgentsHumansFemaleProspective StudiesAntibodies, MonoclonalMedical Oncology

Stichwörter der Autor:innen

HER2HER3antibody‐drug conjugates (ADCs)breast cancertarget selectiontrop‐2

Substanzen

ImmunoconjugatesAntibodies, MonoclonalAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
  • The First Clinical College of Nanjing Medical University, Nanjing, China.
  • Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Personalized Cancer Medicine, Nanjing Medical University, Nanjing, China.

ORCID-Profile: Yongmei Yin

Förderung

  • National Natural Science Foundation of China
  • Chinese Society of Clinical Oncology Science

Zitieren

APA

Qu, F., Lu, R., Liu, Q., Wu, X., Huang, X., Yin, Y., & Li, W. (2024). Antibody–drug conjugates transform the outcome of individuals with low‐HER2‐expression advanced breast cancer. Cancer, 130(S8), 1392-1402. https://doi.org/10.1002/cncr.35205

Vancouver

Qu F, Lu R, Liu Q, Wu X, Huang X, Yin Y, et al. Antibody–drug conjugates transform the outcome of individuals with low‐HER2‐expression advanced breast cancer. Cancer. 2024;130(S8):1392-1402. doi:10.1002/cncr.35205

BibTeX
@article{Qu2024,
  author = {Qu, Fei and Lu, Rongrong and Liu, Qian and Wu, Xuefang and Huang, Xiang and Yin, Yongmei and Li, Wei},
  title = {Antibody–drug conjugates transform the outcome of individuals with low‐HER2‐expression advanced breast cancer},
  journal = {Cancer},
  year = {2024},
  volume = {130},
  number = {S8},
  pages = {1392--1402},
  doi = {10.1002/cncr.35205}
}
Kostenlos starten →